Regenxbio and UPenn Lose Legal Battle Over Muscular Dystrophy Treatment Patent to Sarepta

Published on :

Regenxbio and UPenn Lose Legal Battle Over Muscular Dystrophy Treatment Patent to Sarepta Published on January 6, 2024 In a major legal showdown over patents and innovation, Sarepta Therapeutics (SRPT.O) [….]

Weekly Quick Hits (BioHealth Capital Region) – Week of May 22, 2023

Published on :

Weekly Quick Hits (BioHealth Capital Region) – Week of May 22, 2023 By Sarah EllinwoodMay 26, 2023 Funding, Awards and Collaborations Adaptive Phage Therapeutics Partners with Hebrew University, Hadassah Medical [….]

Weekly Quick Hits (BioHealth Capital Region) – Week of May 15, 2023

Published on :

Weekly Quick Hits (BioHealth Capital Region) – Week of May 15, 2023 By Alex Keown and Sarah EllinwoodMay 19, 2023 Funding, Awards and Collaborations PQE Group US Earns 2023 Great [….]

REGENXBIO Presents Interim Data from Phase II Bridging Study Evaluating the Clinical Performance of RGX-314 Using the NAVXpress™ Manufacturing Platform Process

REGENXBIO Logo
Published on :

REGENXBIO Inc. (Nasdaq: RGNX) today announced results from a Phase II bridging study evaluating the pharmacodynamics, safety and efficacy of RGX-314, a potential one-time therapy delivered subretinally using cGMP material produced by the company’s NAVXpress™ bioreactor platform process. The data is being presented at the Angiogenesis, Exudation, and Degeneration 2023 Conference by Charles C. Wykoff, M.D., PhD., Director of Research at Retina Consultants of Texas; Chairman of Research, Retina Consultants of America; and Deputy Chair of Ophthalmology for the Blanton Eye Institute, Houston Methodist Hospital.

Weekly Quick Hits (BioHealth Capital Region) – Week of January 23, 2023

Published on :

Here’s what’s been happening the BioHealth Capital Region’s Life Science scene the week of January 23, 2023

“DNA Valley” Continues to Flourish in Maryland, the Birthplace of the Human Genome Project

Published on :

Jeff Galvin, the CEO of American Gene TechnologiesⓇ, one of the leading biotech companies in Maryland, has championed the state as “DNA Valley.” And Galvin should know: he came to Maryland after a successful career in Silicon Valley and sees parallels between the early days of an emerging Silicon Valley and what’s going on today in DNA Valley, which currently stretches from Montgomery County and Frederick, Maryland all the way up to Baltimore.

BioHealth Capital Region 2022 Q3 News Recap – Keeping Up the Momentum

Published on :

BioHealth Capital Region 2022 Q3 News Recap – Keeping Up the Momentum A few of BioBuzz’s favorite stories from late summer/early fall Over the past several months, life sciences companies [….]

REGENXBIO Presents Positive Interim Data from and the Expansion of Phase II ALTITUDE® Trial of RGX-314 for the Treatment of Diabetic Retinopathy Using Suprachoroidal Delivery

REGENXBIO Logo
Published on :

REGENXBIO Inc. (Nasdaq: RGNX) today announced additional positive interim data from the ongoing Phase II ALTITUDE® trial of RGX-314 for the treatment of diabetic retinopathy (DR) without center-involved diabetic macular edema (CI-DME) using in-office suprachoroidal delivery. The data were presented at the 55th Annual Retina Society meeting in Pasadena, CA by Lejla Vajzovic, MD, FASRS, Associate Professor of Ophthalmology and Director of Duke Vitreoretinal Fellowship Program, Vitreoretinal Surgery and Disease, Department of Ophthalmology, Duke University School of Medicine. RGX-314 is being investigated as a potential one-time gene therapy for the treatment of wet age-related macular degeneration, DR, and other chronic retinal conditions.